European journal of medical research · 2010 · 31 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyChemotherapy ResistanceCytotoxic Chemotherapy5-Fluorouracil TreatmentAnticancer ChemotherapyAntineoplastic Drug TherapyCell Growth MonitoringConcentration-dependent UptakePlatinum-based RegimensPreclinical Drug Testing
BACKGROUND: Systemic treatment of head and neck squamous cell carcinoma (HNSCC) includes a variety of antineoplastic drugs. However, drug-resistance interferes with the effectiveness of chemotherapy. Preclinical testing models are needed in order to develop approaches to overcome chemoresistance. - METHODS: Ten human cell lines were obtained from HNSCC, including one with experimentally-induced cisplatin resistance. Inhibition of cell growth by seven chemotherapeutic agents (cisplatin, carboplatin, 5- fluorouracil, methotrexate, bleomycin, vincristin, and paclitaxel) was measured using metabolic MTT-uptake assay and correlated to clinically-achievable plasma concentrations. - RESULTS: All drugs inhibited cell growth in a concentration-dependent manner with an IC50 comparable to that achievable in vivo. However, response curves for methotrexate were unsatisfactory and for paclitaxel, the solubilizer cremophor EL was toxic. Cross-resistance was observed between cisplatin and carboplatin. - CONCLUSION: Chemosensitivity of HNSCC cell lines can be determined using the MTT-uptake assay. For DNA-interfering cytostatics and vinca alkaloids this is a simple and reproducible procedure. Determined in vitro chemosensitivity serves as a baseline for further experimental approaches aiming to modulate chemoresistance in HNSCC with potential clinical significance.
21
Jean‐Pierre Pignon, Jean Bourhis, C. Domenge et al. · Cancer/Radiothérapie · 2001 · 702 citations
Medicine, Oncology, Chemotherapy +8
Richard J. Knox, Frank Friedlos, David Lydall et al. · PubMed · 1986 · 499 citations
Medicine, Oncology, Pharmacology +15
Laura Strauss, Christoph Bergmann, Mirosław J. Szczepański et al. · Clinical Cancer Research · 2007 · 442 citations
Life Sciences, Immunology, Oncology +17